Biomarker evaluation in phase I clinical trials of selective PI3K and PI3k/mTOR inhibitors

被引：0
|
作者：
Spoerke, Jill [1 ]
Desai, Rupal [1 ]
Patel, Rajesh [1 ]
Fredrickson, Jill [1 ]
Wang, Yulei [1 ]
Levy, Gallia [1 ]
Gendreau, Steve [1 ]
Lauchle, Jennifer [1 ]
Derynck, Mika [1 ]
Raja, Rajiv [1 ]
Koeppen, Hartmut [1 ]
Hampton, Garret [1 ]
Yan, Yibing [1 ]
Lackner, Mark R. [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-4567
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4567
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    Cancer Biology & Medicine, 2015, 12 (04) : 342 - 354
  • [32] Efficacy of PI3K inhibitors to PI3K mutants in enzyme and cell levels
    Dan, Shingo
    Sugita, Hironobu
    Yamazaki, Kanami
    Yamori, Takao
    CANCER RESEARCH, 2009, 69
  • [33] Imidazopyridazine Inhibitors of PI3Kβ
    Rosse, Gerard
    ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (12): : 1012 - 1013
  • [34] Challenges in the clinical development of PI3K inhibitors
    Massacesi, Cristian
    di Tomaso, Emmanuelle
    Fretault, Nathalie
    Hirawat, Samit
    INOSITOL PHOSPHOLIPID SIGNALING IN PHYSIOLOGY AND DISEASE, 2013, 1280 : 19 - 23
  • [35] Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinase inhibitors.
    Blanco Aparicio, Carmen
    Renner, Oliver
    Gomez-Casero, Elena
    Cebria, Antonio
    Ajenjo, Nuria
    Aguirre, Enara
    Cebrian, David
    Rodriguez de Miguel, Ma Carmen
    Pequeno, Belen
    Isabel Albarran, Ma
    Riesco, Rosario
    Belen Garcia, Ana
    Alvarez, Rosa
    O'Neill, Michael
    Martinez, Sonia
    Pastor, Joaquin
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [36] Dual targeting of pi3k/mTOR
    Fokas, E.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S43 - S43
  • [37] Inhibitors of the PI3K/AKT/mTOR pathway in human malignancies; trend of current clinical trials
    Davoodi-Moghaddam, Zeinab
    Jafari-Raddani, Farideh
    Delshad, Mahda
    Pourbagheri-Sigaroodi, Atieh
    Bashash, Davood
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (16) : 15293 - 15310
  • [38] Inhibitors of the PI3K/AKT/mTOR pathway in human malignancies; trend of current clinical trials
    Zeinab Davoodi-Moghaddam
    Farideh Jafari-Raddani
    Mahda Delshad
    Atieh Pourbagheri-Sigaroodi
    Davood Bashash
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 15293 - 15310
  • [39] Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication
    Campbell, Grant R.
    Bruckman, Rachel S.
    Herns, Shayna D.
    Joshi, Shweta
    Durden, Donald L.
    Spector, Stephen A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2018, 293 (16) : 5808 - 5820
  • [40] Evaluation of nab-sirolimus in combination with PI3K pathway inhibitors to overcome PI3K/mTOR resistance in PI3K-mutant breast cancer cell lines
    Wallace, Sean
    Myint, Khine Nyein
    Hou, Shihe
    Zalath, Maria
    Kwon, Andrew
    McMorran, Brain
    Vivanco, Igor
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
12345